Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
Venetoclax in Combination With Dexamethasone for Resistant Multiple Myeloma
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma
Ixazomib-Based Combination for High-Risk Smoldering Multiple Myeloma
What Effects Do Induction Therapy for Myeloma Have on Circulating Monocytes?
Measurable Residual Disease: The Future of Assessing Treatment Efficacy in Myeloma?
BCMA-Targeted Immunoconjugate for Resistant Multiple Myeloma
Physical Exercise in Patients With Newly Diagnosed Multiple Myeloma
Redefining Value Propositions and Managed Care Considerations in Multiple Myeloma
Insights on Individualizing Treatment of Patients with Multiple Myeloma
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma
Cancer Research Institute Immunotherapy Clinical Trials
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) - Supported Cancer Clinical Trials
NCCN Virtual Reimbursement Resource Room